Welcome to our dedicated page for Adicet Bio SEC filings (Ticker: ACET), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Adicet Bio, Inc. filings document the regulatory record of a clinical-stage biotechnology company developing allogeneic gamma delta T cell therapies. Its Form 8-K reports cover material events, financial results, clinical and regulatory updates for prula-cel and ADI-212, Nasdaq listing-rule matters, and capital-structure disclosures involving common stock and pre-funded warrants.
Proxy filings describe shareholder voting matters, board and governance procedures, executive compensation, equity-award disclosures, and proposals affecting the company’s certificate of incorporation and share structure. These documents connect Adicet’s cell-therapy pipeline with its public-company governance, equity compensation, and financing-related disclosure obligations.
Adicet Bio, Inc. entered an underwriting agreement for an underwritten registered direct offering of 70,001,000 shares of common stock and pre-funded warrants to purchase 10,000,000 shares, all priced at approximately $1.00 per underlying share.
The company expects to receive approximately $74.8 million in net proceeds after underwriting discounts and expenses. Pre-funded warrants have a nominal exercise price of $0.0001 per share, are exercisable on a cashless basis, and include a beneficial ownership cap of 9.99%, which may be increased up to 19.99% with at least 61 days’ prior notice.
The offering is being conducted under Adicet Bio’s effective Form S-3 shelf registration statement and a final prospectus supplement dated October 7, 2025, with closing expected on October 8, 2025, subject to customary conditions.
Adicet Bio (ACET) reports early Phase 1 results for its cell therapy ADI-001 in autoimmune indications based on seven treated patients (five lupus nephritis, two systemic lupus erythematosus) with follow-up of two to nine months. All five LN patients achieved renal response—three complete responses and two partial responses—and all responses remain ongoing. Across all seven patients, rapid and sustained reductions in disease activity scores (SLEDAI-2K and PGA) were observed, and all patients stopped immunosuppressants and reduced corticosteroids to physiologic levels. ADI-001 produced immunologic changes described as elimination of dominant B cell clones and emergence of a new B cell repertoire after a single dose.
Safety through August 31, 2025 was described as generally well tolerated with no serious adverse events, no ICANS, no GvHD/HLH-MAS or prolonged neutropenia; two Grade 1 CRS events and one Grade 1 infection occurred. The company plans an FDA meeting in Q1 2026 to inform pivotal design and anticipates initiating a Phase 2 pivotal study in Q2 2026. The Phase 1 program is open to multiple autoimmune indications with >25 global sites. Capital structure disclosures show 18,184,820 stock options outstanding (weighted-average exercise price $2.56), 8,445,333 pre-funded warrants (exercise price $0.0001), and several share reserve pools.
Adicet Bio (ACET) reported early clinical results for its cell therapy ADI-001 in seven autoimmune patients (five with lupus nephritis (LN) and two with systemic lupus erythematosus (SLE)) with two- to nine-month follow-up. All five LN patients achieved a renal response—three complete responses and two partial responses—and responses remained ongoing. Patients showed rapid, sustained reductions in disease activity scores (SLEDAI-2K and PGA) and discontinued immunosuppressants while tapering corticosteroids. Biomarker changes described an immune reset with elimination of dominant B cell clones and emergence of naive B cells after a single dose. Through August 31, 2025, ADI-001 was generally well tolerated: no serious adverse events or ICANS, two Grade 1 CRS events, one Grade 1 infection, and no GvHD, HLH-MAS, or prolonged neutropenia. The company plans an FDA meeting in Q1 2026 and anticipates initiating a Phase 2 pivotal study in Q2 2026, while continuing Phase 1 enrollment and expanding Phase 1 into additional autoimmune indications.